NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

介入心臟病學的全球市場 - 各設備、終端用戶及各地區的分析與預測:2018-2027年

Global Interventional Cardiology Market: Focus on Devices (Conventional and Advanced), End Users, and Regions - Analysis and Forecast, 2018-2027

出版商 BIS Research Inc. 商品編碼 722940
出版日期 內容資訊 英文 307 Pages
商品交期: 最快1-2個工作天內
價格
介入心臟病學的全球市場 - 各設備、終端用戶及各地區的分析與預測:2018-2027年 Global Interventional Cardiology Market: Focus on Devices (Conventional and Advanced), End Users, and Regions - Analysis and Forecast, 2018-2027
出版日期: 2018年10月10日內容資訊: 英文 307 Pages
簡介

全球介入心臟病學的市場規模預測至2027年將達到249億6,000萬美元的規模。

本報告提供全球介入心臟病學市場相關分析,市場概要和主要市場影響要素,市場競爭環境,市場規模趨勢預測,各市場區隔、各地區的詳細趨勢,主要企業簡介等資訊彙整。

摘要整理

第1章 市場概要

第2章 市場動態

  • 概要
  • 市場成長促進因素
  • 阻礙市場成長要素
  • 市場機會

第3章 產業考察

  • 醫療設備定義
  • 醫療設備的法律規範
  • 專利形勢

第4章 競爭情形

  • 主要的發展策略
  • 市場佔有率分析

第5章 全球介入心臟病學市場:各設備

  • 傳統設備
  • 先進設備

第6章 全球介入心臟病學市場:各終端用戶

  • 醫院
  • 心導管實驗室
  • 門診外科中心
  • 其他

第7章 全球介入心臟病學市場:

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 其他 (RoW)

第8章 企業簡介

  • ABIOMED, Inc.
  • ACIST Medical Systems, Inc.
  • B. Braun Melsungen AG
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • C. R. Bard, Inc.
  • Cook Medical LLC
  • Cordis Corporation
  • Edwards Lifesciences Corporation
  • Life Vascular Devices Biotech S.L.
  • Biosense Webster, Inc
  • Medtronic Plc
  • Merit Medical Systems, Inc
  • Novacam Technologies Inc.
  • Koninklijke Philips N.V.
  • St. Jude Medical
  • Terumo Corporation
  • W. L. Gore & Associates, Inc.
  • Biosensors International Group, Ltd.
  • GE Healthcare

第9章 調查範圍、調查手法

目錄
Product Code: BH068A

Global Interventional Cardiology Market to Reach $24.96 Billion by 2027, Reports BIS Research

Cardiovascular diseases are the major cause of death across the globe. It accounted for 17.3 million deaths in 2015 and is further anticipated to claim 23.6 million lives in 2030 (according to an estimation by the World Health Organization). The rise in geriatric population worldwide has resulted in an increased prevalence of the disease. Moreover, change in eating habits, increased stress, smoking, and alcohol consumption, and disturbed sleeping patterns are some of the key factors contributing to the deteriorating health conditions and to the rise in chronic diseases such as diabetes and cardiac diseases. The International Diabetes Federation has estimated that approximately 415 million people were diabetic in 2015 while the number is expected rise to 642 million worldwide by 2040. Therefore, increased incidence of cardiac diseases accompanied by the rise in healthcare expenditure in the medical device industry are expected to lead the growth of the interventional cardiology market.

The interventional cardiology devices industry is a multi-billion-dollar market which consists of multitudinous companies involved in the manufacturing of catheters, stents, valves, angioplasty balloons, and other cardiac interventional instruments to meet the increasing demand of people suffering from cardiovascular disorders. The advanced cardiac intervention market provides treatment option for a range of cardiovascular diseases including coronary artery disease, heart valve disease, and peripheral vascular disease, among others.

The purpose of this study is to gain a holistic view of the interventional cardiology market in terms of various influencing factors such as recent trends and technological advancements. The scope of this report constitutes of an in-depth study of the global interventional cardiology market, including a thorough analysis of the products across different regions. The market has been segmented into 'devices', 'end users', and 'regions'. The 'devices' segment consists of both conventional and advanced devices. Advanced devices cover the technologically advanced imaging modalities such as IntraVenous UltraSound (IVUS), Fractional Flow Reserve (FFR), and Optical Coherent Tomography (OCT). The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global interventional cardiology market with the help of the key factors driving the market, restraints that can possibly inhibit the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key ecosystem players and key strategies and developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study considers the market share analysis for a comprehensive understanding of the global interventional cardiology market, and assesses the factors governing the same. Detailed product mapping have been included in the report. The market (by region) has been further sub-segmented in various countries, and in each sub-segment the key market trends, list of the key players, and the recent developments that have taken place, have been discussed.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the global interventional cardiology market?
  • What was the market value of the leading segments and sub-segments of the global interventional cardiology market in 2017?
  • How will each segment of the global interventional cardiology market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2027?
  • What are the influencing factors that may affect the market share of the key players?
  • How will the industry evolve during the forecast period 2018-2027?
  • What are the key developmental strategies that are implemented by the key players to sustain in this market?
  • Who are the key players in the interventional cardiology devices and end user market and what are their contributions?
  • What are the major benefits of the implementation of interventional cardiology in different fields of applications including angioplasty, stent placement, coronary thrombectomy, valvuloplasty, percutaneous valve repair or replacement, and congenital heart abnormalities?
  • What is the scope of interventional cardiology in the emerging economies of Asia-Pacific and Latin America?
  • What is the scope for expansion by the key players of the interventional cardiology market in the developed countries of North America and Europe?

The key players who have been contributing significantly to the interventional cardiology market include Abiomed, Inc., ACIST Medical Systems, Inc., B. Braun Melsungen AG, Biosensors International Group, Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical LLC, Cordis Corporation, Edwards Lifesciences Corporation, GE Healthcare, Life Vascular Devices Biotech S.L., Biostense Webster, Inc., Medtronic Plc, Merit Medical Systems, Inc., Novacam Technologies Inc., Koninklijke Philips N.V., St. Jude Medical, Terumo Corporation, and W.L. Gore & Associates, Inc., among others.

Executive Summary

Rising economic burden of chronic diseases is one of the prime concerns that the healthcare and biomedical device industries are currently facing. The high prevalence of chronic diseases such as as cancer, diabetes, cardiovascular diseases, and respiratory diseases, among others, poses one of the significant challenges across the globe. Furthermore, change in eating habits, increased stress, smoking, alcohol consumption, and disturbed sleeping patterns are some of the key factors contributing to the deteriorating health condition in individuals and a rise in lifestyle disorders. It has been estimated that chronic diseases constitute approximately 43% of the global economic burden for diseases and accounts for 60% of the deaths worldwide. It further holds approximately 65% of the annual healthcare cost of any country and comprises one-third of the global population at present. By 2020, the global spending on diseases such as cardiovascular diseases, cancer, and respiratory diseases is expected to reach $4 trillion. Moreover, growing geriatric population has resulted in increased prevalence of lifestyle disease that has led to an upsurge in the demand for advanced medical diagnosis and treatment.

Cardiovascular diseases (CVDs) represent the leading cause of death globally. According to the World Health Organization (WHO), CVD was estimated to claim 17.3 million lives, a number which is anticipated to grow to 23.6 million by 2030. Of these, coronary artery disease and stroke resulted in approximately 7.4 million deaths and 6.7 million deaths respectively. Interventional cardiology deals with the treatment of structural heart diseases specially employing the use of interventional catheters. It involves the treatment of coronary artery disease, heart valve disease, and peripheral vascular disease, among others. With increase in the prevalence of cardiac diseases, advanced interventional cardiology devices are gradually becoming an integral part of the medical device industry.

The purpose of the study is to gain a holistic view of the advanced cardiac intervention market in terms of various factors influencing it such as recent trends and technological advancements of the market. The scope of this report is centered upon conducting a detailed study of the devices allied with the cardiac interventional devices market, which includes both conventional devices and imaging modalities. The global advanced cardiac intervention market is segmented into three different parts: devices, end users, and geography. The global market value was estimated using these three different approaches and was validated with one another. These segments are further segmented into several sub-segments to ease the market estimation.

The global interventional cardiology market was estimated at $14.69 billion in 2017 and is anticipated to reach $24.96 billion by 2027. With the rise in the demand for advanced medical devices to treat cardiovascular diseases, increasing geriatric population with higher life expectancy, and new product launches by several conglomerate companies, the cardiac intervention market is expected to witness moderate growth. The emergence of advanced imaging modalities such as IntraVenous UltraSound (IVUS), Optical Coherent Tomography (OCT), and Fractional Flow Reserve (FFR) has led to the growth of the market.

The global interventional cardiology is segmented by the geographical regions into North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW). North America is the leading contributor to the global interventional cardiology market. However, the Asia-Pacific is expected to grow at a CAGR of 7.12% in the forecast period 2018-2027. The global interventional cardiology market for advanced devices is majorly dominated by the U.S. and the European players.

The key players who have significant contributions to the global interventional cardiology market are Abiomed, Inc., ACIST Medical Systems, Inc., B. Braun Melsungen AG, Biosensors International Group, Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical LLC, Cordis Corporation, Edwards Lifesciences Corporation, GE Healthcare, Life Vascular Devices Biotech S.L., Biostense Webster, Inc., Medtronic Plc, Merit Medical Systems, Inc., Novacam Technologies Inc., Koninklijke Philips N.V., St. Jude Medical, Terumo Corporation, and W.L. Gore & Associates, Inc., among others.

Table of Contents

Executive Summary

1 Market Overview

  • 1.1 Types of Interventional Cardiology Procedures
  • 1.2 Devices Used in Interventional Cardiology

2 Market Dynamics

  • 2.1 Overview
  • 2.2 Market Drivers
    • 2.2.1 Rising Geriatric Population Due to Higher Life Expectancy
    • 2.2.2 Increasing Clinical Evidence of Effectiveness of Advanced Interventional Cardiac Devices
    • 2.2.3 Technological Advancements in Interventional Cardiac Devices
    • 2.2.4 Growing Healthcare Budgetary Allocation in Emerging Economies
    • 2.2.5 Increasing Awareness about Minimally Invasive Surgical Procedure among Patients
  • 2.3 Market Restraints
    • 2.3.1 Stringent Regulatory Requirements for Product Approval and Insufficient Reimbursement Policies
    • 2.3.2 Complications and Risks Associated with the Use of Interventional Cardiac Devices
    • 2.3.3 High Cost of Interventional Cardiology Procedures
  • 2.4 Market Opportunities
    • 2.4.1 Growing Awareness about Advanced Interventional Cardiac Devices
    • 2.4.2 Global Shift toward Value-based Care (VBC)
    • 2.4.3 Increasing Adoption of Innovative Treatment Technologies
    • 2.4.4 Evolving Competitive Landscape of Cardiac Interventions Market

3 Industry Insights

  • 3.1 Definition of Medical Devices
  • 3.2 Framework for Medical Device Regulations
    • 3.2.1 Medical Devices Reporting (MDR)
    • 3.2.2 China Food and Drug Administration (CFDA) Guidelines for Medical Devices
    • 3.2.3 Recommendations for IVUS, FFR, and OCT by Various Cardiology Societies
  • 3.3 Patent Landscape

4 Competitive Landscape

  • 4.1 Key Developmental Strategies
    • 4.1.1 Product Approval
    • 4.1.2 Clinical Study
    • 4.1.3 Product Launch
    • 4.1.4 Acquisitions
    • 4.1.5 Partnership, Agreement, Joint Venture, and Collaboration
    • 4.1.6 Business Expansion
    • 4.1.7 Awards and Recognition
    • 4.1.8 Others
  • 4.2 Market Share Analysis
    • 4.2.1 Market Share for Interventional Cardiology Market for Conventional Devices
    • 4.2.2 Global Optical Coherent Tomography (OCT) Market Share
    • 4.2.3 Global IVUS Market Share

5 Global Interventional Cardiology Market (by Devices)

  • 5.1 Global Interventional Cardiology Market (by Conventional Device)
    • 5.1.1 Cardiac Catheters
    • 5.1.2 PTCA Balloons
    • 5.1.3 Coronary Stents
    • 5.1.4 Cardiac Valves
    • 5.1.5 Others
  • 5.2 Global Interventional Cardiology Market (by Advanced Device)
    • 5.2.1 Intravascular Ultrasound (IVUS)
    • 5.2.2 Fractional Flow Reserve (FFR)
    • 5.2.3 Optical Coherence Tomography (OCT)

6 Global Interventional Cardiology Market (by End User)

  • 6.1 Hospitals
  • 6.2 Cardiac Catheterisation Laboratories
  • 6.3 Ambulatory Surgical Centres
  • 6.4 Others

7 Global Interventional Cardiology Market (by Region)

  • 7.1 North America
    • 7.1.1 The U.S.
    • 7.1.2 Canada
  • 7.2 Europe
    • 7.2.1 Germany
    • 7.2.2 France
    • 7.2.3 The U.K.
    • 7.2.4 Italy
    • 7.2.5 Spain
    • 7.2.6 The Netherlands
    • 7.2.7 Switzerland
    • 7.2.8 Belgium
    • 7.2.9 Sweden
    • 7.2.10 Austria
    • 7.2.11 Rest-of-Europe
  • 7.3 Asia-Pacific
    • 7.3.1 Japan
    • 7.3.2 China
    • 7.3.3 South Korea
    • 7.3.4 Australia
    • 7.3.5 India
    • 7.3.6 Malaysia
    • 7.3.7 Singapore
    • 7.3.8 Taiwan
    • 7.3.9 Rest-of-Asia-Pacific
  • 7.4 Latin America
    • 7.4.1 Brazil
    • 7.4.2 Mexico
    • 7.4.3 Rest-of-Latin America
  • 7.5 Rest-of-the-World (RoW)
    • 7.5.1 Russia
    • 7.5.2 Kingdom of Saudi Arabia (K.S.A.)
    • 7.5.3 South Africa
    • 7.5.4 Others

8 Company Profiles

  • 8.1 ABIOMED, Inc.
    • 8.1.1 Company Overview
    • 8.1.2 Product Offerings for Cardiac Interventions
    • 8.1.3 Financials
      • 8.1.3.1 Financial Summary
    • 8.1.4 Global Presence
    • 8.1.5 Recent Developments
    • 8.1.6 SWOT Analysis
  • 8.2 ACIST Medical Systems, Inc.
    • 8.2.1 Company Overview
    • 8.2.2 Product Offerings for Cardiac Interventions
    • 8.2.3 Corporate Summary
    • 8.2.4 Recent Developments
    • 8.2.5 SWOT Analysis
  • 8.3 B. Braun Melsungen AG
    • 8.3.1 Company Overview
    • 8.3.2 Overall Product Portfolio
      • 8.3.2.1 Product Offerings for Cardiac Interventions
    • 8.3.3 Financials
      • 8.3.3.1 Financial Summary
    • 8.3.4 Global Presence
    • 8.3.5 Recent Developments
    • 8.3.6 SWOT Analysis
  • 8.4 Biotronik SE & Co. KG
    • 8.4.1 Company Overview
    • 8.4.2 Overall Product Portfolio
      • 8.4.2.1 Product Offerings for Cardiac Interventions
    • 8.4.3 Corporate Summary
    • 8.4.4 Global Presence
    • 8.4.5 SWOT Analysis
  • 8.5 Boston Scientific Corporation
    • 8.5.1 Company Overview
    • 8.5.2 Overall Product Portfolio
      • 8.5.2.1 Product Offerings for Cardiac Interventions
    • 8.5.3 Financials
      • 8.5.3.1 Financial Summary
    • 8.5.4 Global Presence
    • 8.5.5 Recent Developments
    • 8.5.6 SWOT Analysis
  • 8.6 C. R. Bard, Inc.
    • 8.6.1 Company Overview
    • 8.6.2 Becton, Dickinson and Company: Company Overview
    • 8.6.3 Overall Product Portfolio
      • 8.6.3.1 Product Offerings for Cardiac Interventions
    • 8.6.4 Financials
      • 8.6.4.1 Financial Summary
    • 8.6.5 Global Presence
    • 8.6.6 Recent Developments
    • 8.6.7 SWOT Analysis
  • 8.7 Cook Medical LLC
    • 8.7.1 Company Overview
    • 8.7.2 Overall Product Portfolio
      • 8.7.2.1 Product Offerings for Cardiac Interventions
    • 8.7.3 Corporate Summary
    • 8.7.4 Global Presence
    • 8.7.5 Recent Developments
    • 8.7.6 SWOT Analysis
  • 8.8 Cordis Corporation
    • 8.8.1 Company Overview
    • 8.8.2 Cardinal Health, Inc.: Company Overview
    • 8.8.3 Overall Product Portfolio
      • 8.8.3.1 Product Offerings for Cardiac Interventions
    • 8.8.4 Financials
      • 8.8.4.1 Financial Summary
    • 8.8.5 Global Presence
    • 8.8.6 Recent Developments
    • 8.8.7 SWOT Analysis
  • 8.9 Edwards Lifesciences Corporation
    • 8.9.1 Company Overview
    • 8.9.2 Overall Product Portfolio
    • 8.9.3 Product Offerings for Cardiac Interventions
    • 8.9.4 Financials
      • 8.9.4.1 Financial Summary
    • 8.9.5 Global Presence
    • 8.9.6 Recent Developments
    • 8.9.7 SWOT Analysis
  • 8.10 Life Vascular Devices Biotech S.L.
    • 8.10.1 Company Overview
    • 8.10.2 Overall Product Portfolio
      • 8.10.2.1 Product Offerings for Cardiac Interventions
    • 8.10.3 Corporate Summary
    • 8.10.4 Recent Developments
    • 8.10.5 SWOT Analysis
  • 8.11 Biosense Webster, Inc
    • 8.11.1 Company Overview
    • 8.11.2 Johnson & Johnson Services, Inc.: Company Overview
    • 8.11.3 Overall Product Portfolio
      • 8.11.3.1 Product Offerings for Cardiac Interventions
    • 8.11.4 Financials
      • 8.11.4.1 Financial Summary
    • 8.11.5 Global Presence
    • 8.11.6 Recent Developments
    • 8.11.7 SWOT Analysis
  • 8.12 Medtronic Plc
    • 8.12.1 Company Overview
    • 8.12.2 Overall Product Portfolio
      • 8.12.2.1 Product Offerings for Cardiac Interventions
    • 8.12.3 Financials
      • 8.12.3.1 Financial Summary
    • 8.12.4 Global Presence
    • 8.12.5 Recent Developments
    • 8.12.6 SWOT Analysis
  • 8.13 Merit Medical Systems, Inc
    • 8.13.1 Company Overview
    • 8.13.2 Overall Product Portfolio
      • 8.13.2.1 Product Offerings for Cardiac Interventions
    • 8.13.3 Financials
      • 8.13.3.1 Financial Summary
    • 8.13.4 Global Presence
    • 8.13.5 Recent Developments
    • 8.13.6 SWOT Analysis
  • 8.14 Novacam Technologies Inc.
    • 8.14.1 Company Overview
    • 8.14.2 Overall Product Portfolio
      • 8.14.2.1 Product Offerings for Cardiac Interventions
    • 8.14.3 Corporate Summary
    • 8.14.4 Global Presence
    • 8.14.5 SWOT Analysis
  • 8.15 Koninklijke Philips N.V.
    • 8.15.1 Company Overview
    • 8.15.2 Overall Product Portfolio
      • 8.15.2.1 Product Offerings for Cardiac Interventions
    • 8.15.3 Financials
      • 8.15.3.1 Financial Summary
    • 8.15.4 Global Presence
    • 8.15.5 Recent Developments
    • 8.15.6 SWOT Analysis
  • 8.16 St. Jude Medical
    • 8.16.1 Company Overview
    • 8.16.2 Abbott Laboratories: Company Overview
    • 8.16.3 Overall Product Portfolio
      • 8.16.3.1 Product Offerings for Cardiac Interventions
    • 8.16.4 Financials
      • 8.16.4.1 Financial Summary
    • 8.16.5 Global Presence
    • 8.16.6 Recent Developments
    • 8.16.7 SWOT Analysis
  • 8.17 Terumo Corporation
    • 8.17.1 Company Overview
    • 8.17.2 Overall Product Portfolio
      • 8.17.2.1 Product Offerings for Cardiac Interventions
    • 8.17.3 Financials
      • 8.17.3.1 Financial Summary
    • 8.17.4 Global Presence
    • 8.17.5 Recent Developments
    • 8.17.6 SWOT Analysis
  • 8.18 W. L. Gore & Associates, Inc.
    • 8.18.1 Company Overview
    • 8.18.2 Overall Product Portfolio
      • 8.18.2.1 Product Offerings for Cardiac Interventions
    • 8.18.3 Corporate Summary
    • 8.18.4 Global Presence
    • 8.18.5 Recent Developments
    • 8.18.6 SWOT Analysis
  • 8.19 Biosensors International Group, Ltd.
    • 8.19.1 Company Overview
    • 8.19.2 Product Offerings for Cardiac Interventions
  • 8.20 GE Healthcare
    • 8.20.1 Company Overview
    • 8.20.2 Product Offerings for Cardiac Interventions

9 Research Scope and Methodology

  • 9.1 Scope of the Report
  • 9.2 Global Interventional Cardiology Market Segmentation
  • 9.3 Research Methodology
    • 9.3.1 Primary Research
    • 9.3.2 Secondary Research
    • 9.3.3 Key Data Points from Primary and Secondary Sources
    • 9.3.4 Data Triangulation
    • 9.3.5 Top-Down Approach
    • 9.3.6 Bottom- Up Approach
  • 9.4 Assumptions and Limitations

List of Tables

  • Table 2.1 Market Drivers - Impact Analysis
  • Table 2.2 Healthcare Expenditure (by Country), $Billion
  • Table.2.3 Market Challenges - Impact Analysis
  • Table 2.4 Comparison of Cardiac Procedure Cost between Major Countries
  • Table 2.5 Market Opportunities - Impact Analysis
  • Table 3.1 Regulatory Tools and General Requirements of the Five Members of the GHTF
  • Table 3.2 CFDA Premarket Overview
  • Table 5.1 Average Procedural Cost of Catheter Ablation
  • Table 5.2 Safety and Effectiveness of Catheter Ablation
  • Table 5.3 List of Partially Bioresorbable Coronary Stents
  • Table 5.4 List of Fully Bioresorbable Coronary Stents
  • Table 5.5 Average Selling Price of Stents (by Country)
  • Table 5.6 FDA Approved Stents, 2017
  • Table 5.7 Average Selling Price of Cardiac Valves (by Company)
  • Table 5.8 Average Selling Price of Tissue Heart Valves (by Company)
  • Table 5.9 Average Selling Price (ASP) of Mechanical Heart Valves (by Company)
  • Table 8.1 ABIOMED, Inc.: Recent Developments
  • Table 8.2 ACIST Medical Systems, Inc.: Recent Developments
  • Table 8.3 B. Braun Melsungen AG: Recent Developments
  • Table 8.4 Biotronik SE & Co. KG: Recent Developments
  • Table 8.5 Boston Scientific Corporation: Recent Developments
  • Table 8.6 Becton, Dickinson and Company: Recent Developments
  • Table 8.7 Cook Medical LLC: Recent Developments
  • Table 8.8 Cardinal Health, Inc.: Recent Developments
  • Table 8.9 Edwards Lifesciences Corporation: Recent Developments
  • Table 8.10 Life Vascular Devices Biotech S.L.: Recent Developments
  • Table 8.11 Biosense Webster (JnJ): Recent Developments
  • Table 8.12 Medtronic Plc: Recent Developments
  • Table 8.13 Merit Medical Systems, Inc: Recent Developments
  • Table 8.14 Koninklijke Philips N.V.: Recent Developments
  • Table 8.15 St. Jude Medical (Abbott): Recent Developments
  • Table 8.16 Terumo Corporation: Recent Developments
  • Table 8.16 W. L. Gore & Associates, Inc.: Recent Developments

List of Figures

  • Figure 1 Global Interventional Cardiology Market, $Billion, 2017-2027
  • Figure 2 Global Interventional Cardiology Market (by Device), 2017 and 2027
  • Figure 3 Global Conventional Interventional Cardiology Device Market (by Product), 2017 and 2027
  • Figure 4 Global Advanced Interventional Cardiology Device Market (by Product), 2017 and 2027
  • Figure 5 Global Interventional Cardiology Market (by End User), 2017 and 2027
  • Figure 6 Global Interventional Cardiology Market (by Region), 2017 and 2027
  • Figure 1.1 Number of Patients Diagnosed With Diabetes, Globally, 2000 and 2030
  • Figure 1.2 Global Interventional Cardiology Market, 2017 and 2027
  • Figure 2.1 Market Dynamics
  • Figure 2.2 Steps for U.S. FDA Pre-Market Approval
  • Figure 3.1 Ideal Conditions for Ensuring Safety and Performance of Medical Devices
  • Figure 3.2 Share of Patents (by Company)
  • Figure 4.1 Share of Key Developmental Strategies, January 2015-May 2018
  • Figure 4.2 Share of Product Approval (by Company), January 2015-May 2018
  • Figure 4.3 Share of Clinical Study (by Company), January 2015-May 2018
  • Figure 4.4 Share of Product Launch (by Company), January 2015-May 2018
  • Figure 4.5 Share of Acquisitions (by Company), January 2015-May 2018
  • Figure 4.6 Share of Partnership, Agreement, Joint Venture, and Collaboration (by Company), January 2015-May 2018
  • Figure 4.7 Share of Business Expansion (by Company), January 2015-May 2018
  • Figure 4.8 Share of Clinical Study (by Company), January 2015-May 2018
  • Figure 4.9 Share of Other Strategy (by Company), January 2015-May 2018
  • Figure 4.10 Market Share for Global Interventional Cardiology Market, 2016 and 2017
  • Figure 4.11 Market Share for Global OCT Devices Market, 2016 and 2017
  • Figure 4.12 Market Share for Global IVUS Market, 2016 and 2017
  • Figure 5.1 Global Interventional Cardiology Market
  • Figure 5.2 Global Interventional Cardiology Market (by Device), 2017-2027
  • Figure 5.3 Global Interventional Cardiology Market (by Conventional Device), 2018-2027
  • Figure 5.4 Global Cardiac Catheter Market, 2017-2027
  • Figure 5.5 Types of Cardiac Conventional Catheters
  • Figure 5.6 Global Cardiac Catheter Market (by Product), 2017-2027
  • Figure 5.7 Global PTCA Balloons Market, 2017-2027
  • Figure 5.8 Global PTCA Balloons Market (by Type), 2017-2027
  • Figure 5.9 Global Coronary Stents Market, 2017-2027
  • Figure 5.10 Types of Coronary Stents
  • Figure 5.11 Global Coronary Stents Market (by Type), 2017-2027
  • Figure 5.12 Global Cardiac Valves Market, 2017-2027
  • Figure 5.13 Types of Cardiac Valves
  • Figure 5.14 Global Cardiac Valves Market (by Type), 2017-2027
  • Figure 5.15 Global Coronary Guidewire Market, 2017-2027
  • Figure 5.16 Global Arteriotomy Closure Devices Market, 2017-2027
  • Figure 5.17 Global Balloon Inflation Devices Market, 2017-2027
  • Figure 5.18 Global Advanced Cardiac Interventions Market
  • Figure 5.19 Global Interventional Cardiology Market (by Advanced Device), 2017-2027
  • Figure 5.20 Global Intravascular Ultrasound (IVUS) Market, 2017-2027
  • Figure 5.21 Global Intravascular Ultrasound (IVUS) Market (by Component), 2017-2027
  • Figure 5.22 Global Fraction Flow Reserve (FFR) Market, 2017-2027
  • Figure 5.23 Global Fractional Flow Reserve (FFR) Market (by Component), 2017-2027
  • Figure 5.24 Global Optical Coherence Tomography (OCT) Market, 2017-2027
  • Figure 5.25 Global Optical Coherent Tomography (OCT) Market (by Component), 2017-2027
  • Figure 6.1 Global Interventional Cardiology Market (by End User)
  • Figure 6.2 Global Interventional Cardiology Market (by End User), $Million, 2017-2027
  • Figure 6.3 Hospitals Interventional Cardiology Market (by Device), $Million, 2017-2027
  • Figure 6.4 Cardiac Catheterisation Laboratories Interventional Cardiology Market (by Device), $Million, 2017-2027
  • Figure 6.5 Ambulatory Surgical Centres Interventional Cardiology Market (by Device), $Million, 2017-2027
  • Figure 6.6 Others Segment Interventional Cardiology Market (by Device), $Million, 2017-2027
  • Figure 7.1 Global Interventional Cardiology Market (by Region and Sub-segment)
  • Figure 7.2 Global Interventional Cardiology Market (by Region), 2017-2027
  • Figure 7.3 North America Interventional Cardiology Market, 2017-2027
  • Figure 7.4 North America Interventional Cardiology Market (by Country), 2017-2027
  • Figure 7.5 North America Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.6 North America Advanced Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.7 The U.S. Interventional Cardiology Market, 2017-2027
  • Figure 7.8 The U.S. Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.9 Canada Interventional Cardiology Market, 2017-2027
  • Figure 7.10 Canada Interventional Cardiology Market (by Devices), 2017-2027
  • Figure 7.11 Europe Interventional Cardiology Market, 2017-2027
  • Figure 7.12 Europe Interventional Cardiology Market (by Country), 2017-2027
  • Figure 7.13 Europe Interventional Cardiology Market (by Devices), 2017-2027
  • Figure 7.14 Europe Advanced Interventional Cardiology Market (by Devices), 2017-2027
  • Figure 7.15 Germany Interventional Cardiology Market, 2017-2027
  • Figure 7.16 Germany Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.17 France Interventional Cardiology Market, 2017-2027
  • Figure 7.18 France Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.19 The U.K. Interventional Cardiology Market, 2017-2027
  • Figure 7.20 The U.K. Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.21 Italy Interventional Cardiology Market, 2017-2027
  • Figure 7.22 Italy Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.23 Spain Interventional Cardiology Market, 2017-2027
  • Figure 7.24 Spain Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.25 Netherlands Interventional Cardiology Market, 2017-2027
  • Figure 7.26 Netherlands Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.27 Switzerland Interventional Cardiology Market, 2017-2027
  • Figure 7.28 Switzerland Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.29 Belgium Interventional Cardiology Market, 2017-2027
  • Figure 7.30 Belgium Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.31 Sweden Interventional Cardiology Market, 2017-2027
  • Figure 7.32 Sweden Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.33 Austria Interventional Cardiology Market, 2017-2027
  • Figure 7.34 Austria Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.35 Rest-of-Europe Interventional Cardiology Market, 2017-2027
  • Figure 7.36 Rest-of-Europe Interventional Cardiology Market, 2017-2027
  • Figure 7.37 Asia-Pacific Interventional Cardiology Market, 2017-2027
  • Figure 7.38 Asia-Pacific Interventional Cardiology Market (by Country), 2017-2027
  • Figure 7.39 Asia-Pacific Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.40 Asia-Pacific Advanced Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.41 Japan Interventional Cardiology Market, 2017-2027
  • Figure 7.42 Japan Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.43 China Interventional Cardiology Market, 2017-2027
  • Figure 7.44 China Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.45 Sotuh Korea Interventional Cardiology Market, 2017-2027
  • Figure 7.46 South Korea Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.47 Australia Interventional Cardiology Market, 2017-2027
  • Figure 7.48 Australia Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.49 India Interventional Cardiology Market, 2017-2027
  • Figure 7.50 India Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.51 Malaysia Interventional Cardiology Market, 2017-2027
  • Figure 7.52 Malaysia Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.53 Singapore Interventional Cardiology Market, 2017-2027
  • Figure 7.54 Singapore Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.55 Taiwan Interventional Cardiology Market, 2017-2027
  • Figure 7.56 Taiwan Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.57 Rest-of-APAC Interventional Cardiology Market, 2017-2027
  • Figure 7.58 Rest-of-APAC Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.59 Latin America Interventional Cardiology Market, 2017-2027
  • Figure 7.60 Latin America Interventional Cardiology Market (by Country), 2017-2027
  • Figure 7.61 Latin America Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.62 Latin America Advanced Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.63 Brazil Interventional Cardiology Market, 2017-2027
  • Figure 7.64 Brazil Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.65 Mexico Interventional Cardiology Market, 2017-2027
  • Figure 7.66 Mexico Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.67 Rest-of-Latin America Interventional Cardiology Market, 2017-2027
  • Figure 7.68 Rest-of-Latin America Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.69 RoW Interventional Cardiology Market, 2017-2027
  • Figure 7.70 RoW Interventional Cardiology Market (by Country), 2017-2027
  • Figure 7.71 RoW Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.72 RoW Advanced Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.73 Russia Interventional Cardiology Market, 2017-2027
  • Figure 7.74 Russia Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.75 K.S.A. Interventional Cardiology Market, 2017-2027
  • Figure 7.76 K.S.A. Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.77 South Africa Interventional Cardiology Market, 2017-2027
  • Figure 7.78 South Africa Interventional Cardiology Market (by Device), 2017-2027
  • Figure 7.79 Others Interventional Cardiology Market, 2017-2027
  • Figure 7.80 Others Interventional Cardiology Market (by Device), 2017-2027
  • Figure 8.1 Share of Public and Private Companies
  • Figure 8.2 ABIOMED, Inc.: Cardiac Interventions Product Portfolio
  • Figure 8.3 ABIOMED, Inc.: Overall Financials 2016-2018
  • Figure 8.4 ABIOMED, Inc.: Net Revenue by Business Segments (2016-2018)
  • Figure 8.5 ABIOMED, Inc.: Net Revenue (by Region) 2016-2018
  • Figure 8.6 ABIOMED, Inc.: Global Presence
  • Figure 8.7 ABIOMED, Inc.: SWOT Analysis
  • Figure 8.8 ACIST Medical Systems, Inc.: Cardiac Interventions Product Portfolio
  • Figure 8.9 ACIST Medical Systems, Inc.: Global Presence
  • Figure 8.10 ACIST Medical Systems, Inc.: SWOT Analysis
  • Figure 8.11 B. Braun Melsugen AG: Product/Service Offerings
  • Figure 8.12 B. Braun Melsugen AG: Overall Product Portfolio
  • Figure 8.14 B. Braun Melsugen AG: Overall Financials (2015-2017)
  • Figure 8.15 B. Braun Melsugen AG: Revenue (by Division) 2015-2017
  • Figure 8.16 B. Braun Melsugen AG: Net Revenue by Region (2015-2017)
  • Figure 8.17 B. Braun Melsungen AG: Global Presence
  • Figure 8.18 B. Braun Melsungen AG: SWOT Analysis
  • Figure 8.19 Biotronik SE & Co. KG: Product/Service Offerings
  • Figure 8.20 Biotronik SE & Co. KG: Cardiac Interventions Product Portfolio
  • Figure 8.21 Biotronik SE & Co. KG: Global Presence
  • Figure 8.22 Biotronik SE & Co. KG: SWOT Analysis
  • Figure 8.23 Boston Scientific Corporation: Product/Service Offerings
  • Figure 8.24 Boston Scientific Corporation: Cardiac Interventions Product Portfolio
  • Figure 8.25 Boston Scientific Corporation: Overall Financials 2014-2017
  • Figure 8.26 Boston Scientific Corporation: Net revenue (by Business Segment) 2014-2017
  • Figure 8.27 Boston Scientific Corporation: Net Revenue (by Region) 2014-2017
  • Figure 8.28 Boston Scientific Corporation: Global Presence
  • Figure 8.29 Boston Scientific Corporation: SWOT Analysis
  • Figure 8.30 Becton, Dickinson and Company: Overall Product/Service Offerings
  • Figure 8.31 Becton, Dickinson & Company: Cardiac Interventions Product Portfolio
  • Figure 8.32 Becton, Dickinson and Company: Overall Financials 2015-2017
  • Figure 8.33 Becton, Dickinson and Company: Revenue (by Business Segment) 2015-2017
  • Figure 8.34 Becton, Dickinson and Company: Revenue (by Region) 2015-2017
  • Figure 8.35 Becton, Dickinson, and Company: Global Presence
  • Figure 8.36 Becton, Dickinson and Company: SWOT Analysis
  • Figure 8.37 Cook Medical LLC: Product/Service Offerings
  • Figure 8.38 Cook Medical LLC: Cardiac Interventions Product Portfolio
  • Figure 8.39 Cook Medical LLC: Global Presence
  • Figure 8.40 Cook Medical LLC: SWOT Analysis
  • Figure 8.41 Cardinal Health, Inc.: Product/Service Offerings
  • Figure 8.42 Cardinal Health, Inc.: Cardiac Interventions Product Portfolio
  • Figure 8.43 Cardinal Health, Inc.: Overall Financials, 2015-2017
  • Figure 8.44 Cardinal Health, Inc.: Net Revenues (by Business Segments), 2015-2027
  • Figure 8.45 Cardinal Health, Inc.: Net Revenue (by Region0, 2015-2017
  • Figure 8.46 Cardinal Health, Inc.: Global Presence
  • Figure 8.47 Cardinal Health, Inc.: SWOT Analysis
  • Figure 8.48 Edwards Lifesciences Corporation: Product/Service Offerings
  • Figure 8.49 Edwards Lifesciences Corporation: Cardiac Interventions Product Portfolio
  • Figure 8.50 Edwards Lifesciences Corporation: Overall Financials 2015-2017
  • Figure 8.51 Edwards Lifesciences Corporation: Net Sales (by Product Segment) 2015-2017
  • Figure 8.52 Edwards Lifesciences Corporation: Net Sales (by Region) 2015-2017
  • Figure 8.53 Edwards Lifesciences Corporation: Global Presence
  • Figure 8.54 Edwards Lifesciences Corporation: SWOT Analysis
  • Figure 8.55 Life Vascular Devices Biotech S.L.: Product/Service Offerings
  • Figure 8.56 Life Vascular Devices Biotech S.L.: Cardiac Interventions Product Portfolio
  • Figure 8.57 Life Vascular Devices Biotech S.L.: Global Presence
  • Figure 8.58 Life Vascular Devices Biotech S.L.: SWOT Analysis
  • Figure 8.59 Johnson & Johnson Services, Inc.: Product/Service Offerings
  • Figure 8.60 Johnson & Johnson Services, Inc.: Cardiac Interventions Product Portfolio
  • Figure 8.61 Johnson & Johnson Services, Inc.: Overall Financials 2014-2017
  • Figure 8.62 Johnson & Johnson Services, Inc.: Net Sales (by Business Segments) 2014-2017
  • Figure 8.63 Johnson & Johnson Services, Inc.: Net Sales (by Region) 2014-2016
  • Figure 8.64 Johnson & Johnson Services, Inc.: Net Sales (by Region), 2017
  • Figure 8.65 Johnson & Johnson Services, Inc.: Net Revenue (by Medical Devices Business Segment) 2014-2017
  • Figure 8.66 Johnson & Johnson Services, Inc.: Global Presence
  • Figure 8.67 Johnson & Johnson Services, Inc.: SWOT Analysis
  • Figure 8.68 Medtronic Plc: Product/Service Offerings
  • Figure 8.69 Medtronic Plc: Cardiac Interventions Product Portfolio
  • Figure 8.70 Medtronic Plc: Overall Financials 2014-2017
  • Figure 8.71 Medtronic Plc: Net Revenue by Business Segment (2014-2017)
  • Figure 8.72 Medtronic Plc: Net Revenue (by Region) 2014-2017
  • Figure 8.73 Medtronic Plc: Global Presence
  • Figure 8.74 Medtronic Plc: SWOT Analysis
  • Figure 8.75 Merit Medical Systems, Inc: Product/Service Offerings
  • Figure 8.76 Merit Medical Systems, Inc: Cardiac Interventions Product Portfolio
  • Figure 8.77 Merit Medical Systems, Inc: Overall Financials 2014-2017
  • Figure 8.78 Merit Medical Systems, Inc: Net Revenue (by Business Segment) 2014-2017
  • Figure 8.79 Merit Medical Systems, Inc: Global Presence
  • Figure 8.80 Merit Medical Systems, Inc: SWOT Analysis
  • Figure 8.81 Novacam Technologies Inc.: Product/Service Offerings
  • Figure 8.82 Novacam Technologies Inc.: Cardiac Interventions Product Portfolio
  • Figure 8.83 Novacam Technologies Inc.: Global Presence
  • Figure 8.84 Novacam Technologies Inc.: SWOT Analysis
  • Figure 8.85 Koninklijke Philips N.V.: Product/Service Offerings
  • Figure 8.86 Koninklijke Philips N.V.: Cardiac Interventions Product Portfolio
  • Figure 8.87 Koninklijke Philips N.V.: Overall Financials (2015-2017)
  • Figure 8.88 Koninklijke Philips N.V.: Net Revenues (by Business Segments) 2015-2017
  • Figure 8.89 Koninklijke Philips N.V.: Net Revenue (by Region) 2015-2017
  • Figure 8.90 Koninklijke Philips N.V.: Global Presence
  • Figure 8.91 Koninklijke Philips N.V.: SWOT Analysis
  • Figure 8.92 Abbott Laboratories: Product/Service Offerings
  • Figure 8.93 Abbott Laboratories: Cardiac Interventions Product Portfolio
  • Figure 8.94 Abbott Laboratories: Overall Financials 2014-2017
  • Figure 8.95 Abbott Laboratories: Revenue (by Business Segment) 2014-2017
  • Figure 8.96 Abbott Laboratories: Revenue (by Region) 2014-2017
  • Figure 8.97 Abbott Laboratories: Revenue by Cardiovascular and Neuromodulation Segment (2017)
  • Figure 8.98 Abbott Laboratories: Global Presence
  • Figure 8.99 Abbot Laboratories: SWOT Analysis
  • Figure 8.100 Terumo Corporation: Product/Service Offerings
  • Figure 8.101 Terumo Corporation: Cardiac Interventions Product Portfolio
  • Figure 8.102 Terumo Corporation: Overall Financials 2015-2017
  • Figure 8.103 Terumo Corporation: Revenue (by Business Segment) 2015-2017
  • Figure 8.104 Terumo Corporation: Net Revenue (by Region) 2015-2017
  • Figure 8.105 Terumo Corporation: Global Presence
  • Figure 8.106 Terumo Corporation: SWOT Analysis
  • Figure 8.107 W. L. Gore & Associates, Inc.: Product/Service Offerings
  • Figure 8.108 W. L. Gore & Associates Inc.: Cardiac Interventions Product Portfolio
  • Figure 8.109 W. L. Gore & Associates, Inc.: Global Presence
  • Figure 8.110 W. L. Gore & Associates, Inc.: SWOT Analysis
  • Figure 8.111 Biosensors International Group, Ltd.: Cardiac Interventions Product Portfolio
  • Figure 8.112 GE Healthcare: Cardiac Interventions Product Portfolio
  • Figure 9.1 Global Interventional Cardiology Market Segmentation
  • Figure 9.2 Research Methodology
  • Figure 9.3 Key Data Points from Primary and Secondary Sources
  • Figure 9.4 Data Triangulation
  • Figure 9.5 Top-down Approach: Global Interventional Cardiology Market
  • Figure 9.6 Bottom-up Approach: Global Interventional Cardiology Market
  • Figure 9.7 Assumptions and Limitations